Cryopreserved Umbilical Cord Allografts Show Pain Reduction in Cervical Paraspinal Muscle Degeneration: 31-Patient Study
核心洞察
A 31-patient observational study published in Medical Research Archives evaluated cryopreserved human umbilical cord tissue allografts for cervical paraspinal muscle degeneration (搜索) and enthesopathy (搜索).
Patients receiving ultrasound-guided applications across C1 to C7 reported reductions in NPRS pain scores and WOMAC function scores, with the triple-application group showing the largest improvements.
No adverse events or complications were observed during the study period across all application groups.
A peer-reviewed observational study published in Medical Research Archives, the journal of the European Society of Medicine, has reported that cryopreserved human umbilical cord tissue allografts applied to the cervical paraspinal muscles and entheses were associated with reductions in patient-reported pain and improvements in function scores, with no adverse events observed. The study, conducted across multiple clinics and drawing from an observational repository overseen by Regenative Labs (搜索), enrolled 31 patients with imaging-confirmed cervical paraspinal muscle degeneration (搜索) and enthesopathy (搜索).
The findings, published on July 29, 2026, represent the latest contribution to a growing body of evidence on the homologous use of birth tissue allografts in musculoskeletal applications. Regenative Labs (搜索), an FDA-registered manufacturer of cryopreserved Wharton's Jelly allografts based in Pensacola, Florida, now counts 19 peer-reviewed papers in its research library.
Study Design and Patient Population
All 31 patients had exhausted at least three months of conservative care prior to receiving the allograft. Participants received one to three ultrasound-guided applications of a cryopreserved umbilical cord tissue allograft, placed at targeted sites spanning the cervical spine from C1 to C7. Each application delivered 2 mL (150 mg) of allograft material.
Outcomes were tracked using two validated instruments: the Numeric Pain Rating Scale (NPRS) and the Western Ontario and McMaster Universities Arthritis Index (WOMAC). Patients were not randomized to application groups, and the authors did not report between-group comparisons.
The study was authored by Conrad Tamea, Jeff Buchalter, Jason Capra, Tracie Gilliland, Heather Johnson, Lonnie Peets, Naomi Lambert, Alexis Lee, and Tyler Barrett.
Reported Outcomes Across Application Groups
The authors reported reductions in average NPRS and WOMAC scores from the initial visit to the final visit across all application groups. In within-group analyses, statistically significant reductions in pain and WOMAC measures were reported for the single and double application groups across their respective timelines. The triple application group demonstrated statistically significant reductions across all measured scales from the initial visit to the final visit.
Mean NPRS pain scores moved from 5.20 to 4.13 in the single-application group, from 6.00 to 3.11 in the double-application group, and from 7.00 to 1.86 in the triple-application group. WOMAC Total scores shifted from 39.73 to 22.80 (single), 35.44 to 33.67 (double), and 51.57 to 43.29 (triple). Improvements in quality-of-life scores were noted in the single and triple application groups.
Critically, the authors reported that no adverse events or complications were observed during the study period.
Structural Rationale and Mechanism
Human umbilical cord tissue contains a collagen-rich extracellular matrix. In the published discussion, the authors describe the structural similarity between this matrix and the collagen and fibrocartilage of the cervical paraspinal entheses and muscle as the basis for using the allograft to supplement and support defective tissue in homologous locations.
Company Perspective on Evidence Generation
"Birth tissue allografts continue to draw interest in healthcare markets worldwide, and that interest has to be met with rigorous research and transparent reporting," said Tyler Barrett, Chief Executive Officer of Regenative Labs (搜索) and a co-author of the study. "Publishing observational data as the authors recorded it, including the measures that moved less than others, is how a real evidence base gets built. That is the standard we hold ourselves to."
The company stated it will continue to invest in observational research and transparent reporting of patient-reported outcomes as it works toward obtaining documentation needed to export its products internationally. Physicians interested in the published evidence library or in participating in the observational repository can contact Regenative Labs (搜索) directly.